Melanoma Therapeutics Market to Reach USD 19.2 Billion by 2034, Driven by Rising Skin Cancer Incidence and Targeted Therapy Adoption at 10.6% CAGR

The global melanoma therapeutics market was valued at US$ 6.4 Bn in 2023 and is expected to grow at a CAGR of 10.6% from 2024 to 2034, reaching US$ 19.2 Bn by the end of 2034. Rising incidence of skin cancer and increasing preference for targeted therapies are key factors driving the melanoma therapeutics market.

The market is also benefiting from a robust pipeline of drugs and biologics aimed at improving treatment outcomes for patients with melanoma. Growing availability of early detection and minimally invasive treatment options, along with increasing public awareness about skin cancer, is encouraging investment in melanoma research and therapeutic development.

Generic drugs are expected to contribute to market revenue in low- and middle-income countries because of their cost-effectiveness. At the same time, companies are exploring advanced approaches, including extracellular vesicles as delivery vehicles, to improve melanoma treatment.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=80829

Analyst Viewpoint

The rising incidence of skin cancer and increasing focus on targeted therapy are primarily responsible for the growth of the melanoma therapeutics market. A strong pipeline of drugs and biologics is expected to influence the development of the melanoma therapeutics landscape during the forecast period.

Companies are also examining clinical trial data generated over the past several years to develop improved versions of melanoma therapies. Research into extracellular vesicles as delivery vehicles represents another area of interest as pharmaceutical and biotechnology companies seek innovative approaches to melanoma treatment.

Generic medicines are likely to support market expansion in low- and middle-income countries because of their comparatively cost-effective nature.

Melanoma Therapeutics Market Overview

Melanoma develops when healthy melanocytes, the cells responsible for producing melanin and giving skin its color, undergo changes that cause them to become cancerous. Increasing exposure to ultraviolet radiation is associated with the development of melanoma.

The U.S. Environmental Protection Agency has highlighted concerns regarding ozone layer depletion and increasing ultraviolet radiation reaching the Earth. This factor is contributing to concerns surrounding melanoma and is expected to support demand for melanoma therapeutics.

Treatment options have also evolved, with early detection and therapies designed to minimize side effects becoming increasingly available. Combining different treatment approaches can contribute to improved survival outcomes. Growing awareness of skin cancer is encouraging patients to seek diagnosis and treatment while motivating market participants to increase research investment.

According to the American Cancer Society, melanoma risk increases with age and is likely to affect individuals aged 60 and above.

The melanoma therapeutics market includes branded and generic drugs. Generic drugs are expected to account for a larger share during the forecast period, particularly due to their cost-effectiveness. According to the National Cancer Institute, desmoplastic melanoma can be treated using the immunotherapy drug Keytruda, as indicated by Phase II clinical trial findings.

Growing Cases of Skin Cancer Propelling Demand for Melanoma Oncology Treatments

The growing incidence of melanoma is a major factor contributing to demand for effective oncology treatments. Melanoma occurs when melanocytes develop into cancer cells, potentially leading to disease progression and spread.

Melanoma therapeutics include medicines that target proteins involved in immune-system regulation. Some treatments help restore immune activity against melanoma cells. Atezolizumab, marketed as Tecentriq, is among the drugs used in melanoma treatment.

Surgery remains an important treatment option for severe melanoma cases. Broad local excision can be used to remove melanoma along with surrounding normal tissue. Skin grafting may subsequently be performed to cover wounds resulting from surgery.

Chemotherapy can also be used in certain situations, including metastatic melanoma. It can help shrink tumors that have spread to different areas of the body.

The treatment landscape is also expanding through cellular therapies. The U.S. FDA approved Amtagvi, or lifileucel, as the first cellular therapy intended to treat adult patients with melanoma that cannot be surgically removed.

The global burden of melanoma further highlights the need for effective treatments. According to the International Agency for Research on Cancer, approximately 330,000 new melanoma cases were recorded worldwide in 2022, with around 60,000 deaths attributed to the disease.

Increasing incidence of skin cancer and the need to improve treatment options are therefore contributing significantly to melanoma therapeutics market growth.

Inclination toward Targeted Therapy Driving Melanoma Medication Landscape

Targeted therapy is emerging as an important component of the melanoma treatment landscape. It involves medicines designed to interfere with abnormal molecules within cancer cells and regulate their growth.

Targeted therapies are systemic treatments, meaning the drugs can travel through the bloodstream and reach different areas of the body. This characteristic makes systemic treatments particularly relevant when cancer spreads beyond its original site.

Approximately 50% of melanoma cells are known to contain genetic mutations in the BRAF protein. BRAF and MEK are involved in regulating cell growth. Mutations in BRAF can cause abnormal cell development and uncontrolled cell division.

Targeted therapies can block the activity of mutated BRAF and MEK proteins, thereby slowing or stopping the growth of melanoma cells. Increasing awareness and adoption of such approaches are contributing to the expansion of the melanoma medication landscape.

In March 2022, the U.S. FDA approved a therapy for patients with inoperable or metastatic melanoma combining two immunotherapy agents, relatlimab, an anti-LAG-3 agent, and nivolumab, an anti-PD-1 agent.

The growing focus on molecularly targeted and immune-based approaches is expected to support the melanoma therapeutics market as treatment strategies become increasingly focused on the biological characteristics of cancer cells.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=80829

Melanoma Therapeutics Market Regional Insights

North America dominated the global melanoma therapeutics market in 2023 and is expected to maintain its leading position during the forecast period. The region's dominance is attributed primarily to the high number of patients affected by skin cancer in the U.S.

According to updates from the American Academy of Dermatology Association in 2022, skin cancer is among the most common cancers in the U.S. The association also stated that approximately 20% of Americans would develop cancer during their lifetime.

The American Cancer Society reported 99,780 new melanoma cases in the U.S. in 2022, while approximately 7,650 individuals died from the disease during the same year. The significant disease burden is supporting demand for melanoma diagnosis, treatment, and therapeutic research.

Asia Pacific is also witnessing growth in the melanoma therapeutics market. Increasing incidence of skin cancer in countries such as India and government initiatives to strengthen cancer treatment are contributing to market development.

The National Cancer Grid, an initiative of the Government of India, has established a digital oncology center aimed at improving cancer treatment through digital technologies. Such initiatives are contributing to the development of the regional cancer-treatment ecosystem.

Analysis of Key Players in the Melanoma Therapeutics Market

Companies operating in the melanoma therapeutics market are focusing on product development and innovative treatment approaches to strengthen their positions. Pharmaceutical and biotechnology companies are investing in immunotherapies, targeted therapies, cellular therapies, and other approaches aimed at addressing melanoma.

In December 2022, Moderna announced a personalized mRNA vaccine in combination with Merck's Keytruda. The therapy was reported to reduce the risk of death in patients with stage 3 and stage 4 melanoma by 44%.

Major companies profiled in the melanoma therapeutics market include Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Merck & Co., Inc., Amgen Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories.

These companies are evaluated based on company overview, business strategies, financial performance, product portfolios, and business segments.

Competitive Landscape of the Melanoma Therapeutics Market

The competitive landscape is characterized by pharmaceutical companies pursuing new therapies and regulatory approvals across melanoma and related treatment areas.

In January 2022, Pfizer obtained U.S. FDA approval for CIBINQO, an oral once-daily Janus kinase 1 inhibitor, for adults with refractory moderate-to-severe atopic dermatitis, particularly where the condition was not adequately controlled through biologics or other systemic drugs.

Also in January 2022, Immunocore received U.S. FDA approval for KIMMTRAK, or tebentafusp-tebn, for the treatment of metastatic or unresectable uveal melanoma.

Regulatory approvals and advances in immunotherapy and targeted treatment continue to influence competition across the broader melanoma therapeutics landscape.

Melanoma Therapeutics Market Segmentation

Based on therapy type, the melanoma therapeutics market is segmented into chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgery. These treatment modalities represent different approaches used in the management of melanoma depending on disease characteristics and treatment requirements.

By disease indication, the market segmentation provided in the source includes chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgery.

Based on end user, the market is divided into hospitals and specialty clinics, homecare settings, and others, including academic institutes. Hospitals and specialty clinics represent important settings for melanoma diagnosis and treatment, while homecare settings can support treatment and patient management outside conventional healthcare facilities.

The market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Country-level coverage includes the U.S., Canada, Germany, the U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, South Africa, and GCC countries.

Melanoma Therapeutics Market Outlook

The global melanoma therapeutics market is poised for significant growth through 2034, supported by the increasing incidence of skin cancer, growing awareness of melanoma, and continued development of targeted and immune-based treatment approaches.

The emergence of cellular therapies, personalized treatment approaches, and a strong pipeline of drugs and biologics is expanding the therapeutic landscape. At the same time, generic medicines are expected to support access and revenue growth in low- and middle-income countries due to their cost-effectiveness.

North America is expected to remain the leading regional market, supported by the substantial burden of skin cancer in the U.S. Asia Pacific is also expected to offer growth opportunities as countries strengthen cancer treatment infrastructure and introduce digital technologies into oncology care.

Overall, the global melanoma therapeutics market is projected to increase from US$ 6.4 Bn in 2023 to US$ 19.2 Bn by 2034, expanding at a 10.6% CAGR from 2024 to 2034, driven by rising skin cancer incidence and increasing preference for targeted therapy.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=80829<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Kinase Inhibitors Market

Monoclonal Antibodies Market

Osteoarthritis Drugs Market

Anticancer Drugs Market

Cancer Immunotherapy Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com